DISCLAIMER: By making this blog post, I do not intend to infringe on anyone’s rights.
I decided to find the revisions made in the 13th Edition of Katzung’s Basic and Clinical Pharmacology, since I (and many other pharmacy and medical students) have the 2012/12th Edition of Katzung — I am presenting this for people to decide whether they think the changes are significant enough to warrant buying the new edition, or if they believe the 12th edition will suffice for the time being.
The cover itself has a few changes, apart from the edition number and the image used on it. For instance, Susan B. Masters, PhD, is no longer listed on the cover. On examining the second page of the book, she is not attributed as an associate editor of the book. Anthony J. Trevor, PhD is mentioned as the sole associate editor of the 2015 edition.
In the preface of the 13th Edition, the following significant revisions are mentioned:
- Addition of a chapter on pharmacogenomics, an area of increasing importance in all aspects of pharmacology. The drug development and regulation material previously covered in Chapter 5 has been incorporated into Chapter 1.
- A generic name/trade name table appears at the conclusion of most chapters, providing a rapid reference for these names.
- Many revised illustrations in full color provide significantly more information about drug mechanisms and effects and help to clarify important concepts.
- Major revisions of the chapters on sympathomimetic, diuretic, antipsychotic, antidepressant, antidiabetic, antiinflammatory, and antiviral drugs, prostaglandins, nitric oxide, hypothalamic and pituitary hormones, central nervous system neurotransmitters, immunopharmacology, and toxicology.
- Continued expansion of the coverage of general concepts relating to newly discovered receptors, receptor mechanisms, and drug transporters.
- Descriptions of important new drugs released through August 2014.
In particular, changes that have been made to pages before the preface follow after the cut (click “Keep reading”.)
Changes to the Schedule of Controlled Drugs (back side of front cover):
“… morphine (Avinza, Kadian, MSContin, Roxanol,) hydrocodone and hydrocodone combinations (Zohydro ER, Hycodan, Vicodin, Lortab), hydromorphone (Dilaudid), orxymorphone (Exalgo), oxycodone…”
“… The following opioids in combination with one or more active non-opioid ingredients, provided the amount does not exceed that shown:
Codeine and dihydrocodeine: not to exceed 1800 mg/dL or 90 mg/ tablet or other dosage unit
[Dihydrocodeinone omitted from list.]
Opium: 500 mg/dL or 25 mg/5 mL or other dosage unit (paregoric) ”
Schedule II barbiturates in mixtures with noncontrolled drugs or in suppository dosage form
Barbiturates (butabarbital [Butisol], butalbital [Fiorinal])
Ketamine (Ketalar) …”
Changes to the Contents/Table of Contents:
I included this, because changes in authorship will almost ascertain which chapters have been appended or revised.
Section I: Basic Principles
Chapter 5 in the 13th Edition is titled “Pharmacogenomics” and is authored by Jennifer E. Hibma, PharmD and Kathleen M. Giacomini, PhD, replacing the corresponding chapter in the 12th Edition (“Development & Regulation of Drugs” by Bertram G. Katzung, MD, PhD.)
Section III: Cardiovascular-Renal Drugs
Chapter 15 in the 13th Edition is still titled “Diuretic Agents”, but is now authored by Ramin Sam, MD, David Pearce, MD, and Harlan E. Ives, MD, PhD, instead of just Ives.
Section IV: Drugs with Important Actions on Smooth Muscle
Chapter 20 in the 13th Edition is still titled “Drugs Used in Asthma”, but is now authored by Joshua M. Galanter, MD, and Homer A. Boushey, MD , instead of just Boushey.
Section V: Drugs that Act in the Central Nervous System
Chapter 21: Introduction to the Pharmacology of CNS Drugs is now authored by John A. Gray, MD, PhD and Roger A. Nicoll, MD, instead of just Nicoll.
Chapter 22: Sedative-Hypnotic Drugs is only authored by Anthony J. Trevor, PhD now. The 12th Edition listed Walter L. Way, MD as another contributor.
Chapter 23: The Alcohols is now attributed to Susan B. Masters, PhD and Anthony J. Trevor, PhD, instead of just Masters.
Chapter 29: Antipsychotic Agents and Lithium is now authored by Charles DeBattista, MD. The 12th Edition lists Herbert Meltzer, MD, PhD as its author.
Chapter 31: Opioid Agonists & Antagonists replaced Ramana K. Naidu, MD (12th Edition) with Walter L. Way, MD, as a contributor.
Section VI: Drugs Used to Treat Diseases of the Blood, Inflammation & Gout
Chapter 33: Agents Used in Cytopenias; Hematopoietic Growth Factors is now authored by James L. Zehnder, MD, instead of Susan B. Masters, PhD.
Chapter 36: Nonsteroidal Anti-Inflammatory Drugs, Disease-Modifying Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout is now authored by Nabeel H. Borazan, MD, & Daniel E. Furst, MD. The 12th Edition had Furst, Robert W. Ulrich, PharmD, and Shraddha Prakash, MD as contributors.
Section VII: Endocrine Drugs
Chapter 37: Hypothalamic & Pitutary Hormones is now authored by Roger K. Long, MD, and Hakan Cakmak, MD. (Susan B. Masters, PhD, and Stephen M. Rosenthal, MD in the 12th Edition.)
Chapter 41: Pancreatic Hormones & Antidiabetic Drugs adds Umesh Masharani, MBBS, MRCP (UK) as a contributor.
Chapter VII: Chemotherapeutic Drugs
Chapter 55: Immunopharmacology no longer attributes Emmanuel T. Akporiaye, PhD as a contributor.